Annual Variant-Targeted Vaccination to Prevent Severe COVID-19 in Cohorts With Vaccine-Derived and Hybrid Immunity.

ABSTRACT:

Background

Current coronavirus disease 2019 (COVID-19) vaccine recommendations in the United States (US) provide guidance for adults to receive at least annual variant-targeted vaccination. We sought to estimate the strength and durability of protection from annual variant-targeted vaccination against severe COVID-19 illness in individuals with vaccine-derived and hybrid immunity.

Methods

We emulated a target trial using an electronic health record-based, propensity score-matched (1:1) cohort of US Veterans. Booster-vaccinated adults were eligible for a variant-targeted messenger RNA (mRNA) booster starting 1 September 2022. Matched sets of those who did and did not receive the variant-targeted booster dose were identified on a weekly basis, and the cohort was followed until

SUBMITTER: Kelly JD 

PROVIDER: S-EPMC12448581 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature